Chimeric molecules to target proteins for ubiquitination and degradation

Methods in Enzymology

Volumn 399, Issue , 2005, Pages 833-847

  Sakamoto, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANDROGEN RECEPTOR; ESTROGEN; METHIONYL AMINOPEPTIDASE; PROTEASOME; UBIQUITIN PROTEIN LIGASE;

ARTICLE; BINDING AFFINITY; CANCER; CELL CYCLE; CHIMERA; COMPLEX FORMATION; DEGENERATIVE DISEASE; ENZYME ANALYSIS; EUKARYOTE; HUMAN; IN VITRO STUDY; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UBIQUITINATION;

EUKARYOTA;

EID: 28844464657     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(05)99054-X     Document Type: Review

References (23)

1. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system Nat. Immunol. 3 2002 20 26
2. Ciechanover A., Orian A., and Schwartz A.L. Ubiquitin-mediated proteolysis: Biological regulation via destruction Bioessays 22 2000 442 451
3. Debes J.D., Schmidt L.J., Huang H., and Tindall D.J. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6 Cancer Res. 62 2002 5632 5636
4. Deshaies R.J. SCF and Cullin/Ring H2-based ubiquitin ligases Annu. Rev. Cell Dev. Biol. 15 1999 435 467
5. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., and Ratcliffe P.J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell 107 2001 43 54
6. Griffith E.C., Su Z., Turk B.E., Chen S., Chang Y.H., Wu Z., Biemann K., and Liu J.O. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin Chem. Biol. 4 1997 461 471
7. Hon W.C., Wilson M.I., Harlos K., Claridge T.D., Schofield C.J., Pugh C.W., Maxwell P.H., Ratcliffe P.J., Stuart D.I., and Jones E.Y. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL Nature 417 2002 975 978
8. Howell A., Howell S.J., and Evans D.G. New approaches to the endocrine prevention and treatment of breast cancer Cancer Chemother. Pharmacol. 52 Suppl. 1 2003 S39 S44
9. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., and Kaelin W.G. Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing Science 292 2001 464 468
10. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome Nat. Rev. Cancer 2 2002 673 682
11. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity Annu. Rev. Immunol. 18 2000 621 663
12. Kirschberg T.A., VanDeusen C.L., Rothbard J.B., Yang M., and Wender P.A. Arginine-based molecular transporters: The synthesis and chemical evaluation of releasable taxol-transporter conjugates Org. Lett. 5 2003 3459 3462
13. Lyapina S.A., Correll C.C., Kipreos E.T., and Deshaies R.J. Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein Proc. Natl. Acad. Sci. USA 95 1998 7451 7456
14. Murray A.W. Cell cycle extracts Methods Cell Biol. 36 1991 581 605
15. Sakamoto K.M. Ubiquitin-dependent proteolysis: Its role in human diseases and the design of therapeutic strategies Mol. Genet. Metab. 77 2002 44 56
16. Sakamoto K.M., Kim K.B., Kumagai A., Mercurio F., Crews C.M., and Deshaies R.J. Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation Proc. Natl. Acad. Sci. USA 98 2001 8554 8559
17. Sakamoto K.M., Kim K.B., Verma R., Ransick A., Stein B., Crews C.M., and Deshaies R.J. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation Mol. Cell Proteomics 2 2003 1350 1358
18. Schneekloth J.S. Jr., Fonseca F.N., Koldobskiy M., Mandal A., Deshaies R., Sakamoto K., and Crews C.M. Chemical genetic control of protein levels: Selective in vivo targeted degradation J. Am. Chem. Soc. 126 2004 3748 3754
19. Sin N., Meng L., Wang M.Q., Wen J.J., Bornmann W.G., and Crews C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 Proc. Natl. Acad. Sci. USA 94 1997 6099 6103
20. Verma R., Aravind L., Oania R., McDonald W.H., Yates J.R. 3rd, Koonin E.V., and Deshaies R.J. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome Science 298 2002 611 615
21. Verma R., Chen S., Feldman R., Schieltz D., Yates J., Dohmen J., and Deshaies R.J. Proteasomal proteomics: Identification of nucleotide-sensitive proteasome-interacting proteins by mass spectrometric analysis of affinity-purified proteasomes Mol. Biol. Cell 11 2000 3425 3439
22. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., and Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters Proc. Natl. Acad. Sci. USA 97 2000 13003 13008
23. Yeh J.R., Mohan R., and Crews C.M. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest Proc. Natl. Acad. Sci. USA 97 2000 12782 12787